NPS is committed to developing new treatment options for patients with rare gastrointestinal and endocrine disorders who have few, if any, therapeutic options. We have received approval for Gattex®(U.S.)/Revestive®(EU) (teduglutide [rDNA origin]) for injection for the treatment short bowel syndrome patients who are dependent on parenteral support. We are also developing Natpara® (recombinant human parathyroid hormone (rhPTH (1-84)) for hypoparathyroidism and plan to submit our Biologic License Application to the FDA in 2013. We have provided information within this section to further educate you about SBS and hypoparathyroidism.
“At NPS Pharmaceuticals, addressing patients' unmet needs is central to everything we do. NPS is deeply committed to ensuring patients with rare diseases have burden-free access to our FDA-approved treatments. NPS Advantage is a support program helping each patient and their healthcare professionals get the answers they need about NPS therapies.”
Sr. Vice President & Chief Commercial Officer